New Report Signals Europe's Cannabis Markets Enter Growth Phase

Germany's Partial Legalization Drives Continental Momentum

Germany's April 2024 implementation of limited adult-use legalization has catalyzed policy reconsideration across the European Union, with neighboring states now reassessing their enforcement postures. The German model permits home cultivation and nonprofit cannabis social clubs. It stops short of commercial retail. But it's creating legal consumer demand that cross-border operators are positioning to serve.

The report notes that Germany's BfArM (Federal Institute for Drugs and Medical Devices) has issued 14 cultivation licenses since 2019, with domestic production capacity now exceeding 10,000 kilograms annually. That figure remains well below domestic medical demand—estimated at 22,000 kg in 2025—creating sustained import demand that benefits licensed producers in Canada, Portugal, and the Netherlands.

German lawmakers are expected to revisit commercial retail frameworks in late 2026, with coalition parties signaling openness to regulated dispensary models if social-club implementation proceeds without public-health disruptions. That timeline positions Germany as the likely anchor market for European cannabis commerce through 2028.

Netherlands Formalizes Supply Chain After Decades of Toleration

The Netherlands' long-awaited shift from toleration to regulation entered its operational phase in January 2026, when ten licensed cultivators began supplying Amsterdam and Tilburg coffeeshops under a closed-loop pilot program. The experiment—formalized under the Wet gesloten coffeeshopketen (Closed Coffeeshop Chain Act)—ends the paradox in which retail sales were tolerated but supply remained criminal.

Key pilot parameters include:

• Ten municipal regions participating through 2028, covering approximately 80 coffeeshops
• Licensed cultivators subject to track-and-trace oversight and potency caps (15% THC for flower, 30% for concentrates)
• Retail pricing within 10% of legacy-market rates to discourage parallel commerce
• Quarterly reporting to the Ministry of Health, Welfare and Sport on sales volumes, product mix, and consumer demographics

Early data from the first quarter shows coffeeshop sales within pilot regions declined 8% compared to the prior year, a figure ministry officials attribute to consumer adjustment periods and initial supply constraints. Expansion to additional municipalities depends on pilot outcomes, with a formal review scheduled for Q1 2027.

Switzerland Advances Federal Adult-Use Framework

Switzerland's Federal Council submitted draft adult-use legislation to Parliament in March 2026, proposing a federally regulated retail model that would replace the current patchwork of municipal pilot programs. The proposal builds on data from Basel, Zurich, and Geneva trials that enrolled 3,200 participants since 2022 under research exemptions.

Under the federal framework, licensed dispensaries would operate in cantons that opt in via referendum, with cultivation and processing limited to domestic operators. THC potency caps mirror the Dutch model (15% flower, 30% extracts), and retail licenses would be capped at one per 10,000 residents to limit density.

Parliamentary debate begins in September 2026. Passage is expected in early 2027 if center-left and Green parties maintain coalition discipline. The Swiss model's emphasis on cantonal opt-in and domestic supply chain control positions it as a middle path between Germany's nonprofit clubs and the Netherlands' coffeeshop infrastructure.

Investment and Trade Implications

The report identifies three structural shifts reshaping European cannabis capital flows: consolidation among EU-GMP certified cultivators, cross-border medical distribution partnerships, and early-stage positioning by North American MSOs in anticipation of retail liberalization.

EU-GMP (Good Manufacturing Practice) certification remains the regulatory bottleneck for export-oriented producers. Fewer than 40 facilities EU-wide hold the certification required for medical cannabis distribution across member states, concentrating production in Portugal, the Netherlands, and Denmark. Portuguese cultivators—led by Tilray's Cantanhede facility—exported an estimated 8,500 kg to Germany and Italy in 2025, capturing roughly 40% of the German import market.

North American operators including Curaleaf and Trulieve have established European subsidiaries or partnership agreements with EU-GMP holders, positioning for retail market entry if and when commercial frameworks advance. These arrangements typically involve licensing intellectual property (cultivation genetics, retail branding) rather than direct capital deployment, reflecting uncertainty around timeline and regulatory structure.

The next 18 months will clarify whether Europe's regulatory momentum translates into a unified cannabis market or remains a patchwork of national experiments. Germany's 2026 retail review, the Dutch pilot expansion decision, and Swiss parliamentary action represent the three near-term signals investors and operators are tracking most closely. For full background on this story, see the CannIntel topic hub on Europe Cannabis Markets.